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ABSTRACT 
  
This study investigates the pharmacodynamic interaction 
between some B-blockers and chemotherapeutic agents.  The study 
is relating the possible Pharmacodynamic interaction among 
patients with cardiovascular diseases in such tropical areas like 
Sudan, where tropical disease like; malaria, leishmaniasis and 
tuberculosis exist. 
The β-blockers been selected for the study were 
propranolol and atenolol. The interacting chemotherapeutic agents 
involved in this study were, isoniazed (Antilubercular), 
chloroquine phosphate and quinine dihydrochloride. 
(Antimalairals).  
The pharmacological experimental models used to 
investigate the pharmacodynamic interaction are the following 
models: 
(A) The in situ frog heart. 
(B) The isolated rabbit aortic strip. 
(C) The rat vas deferens. 
As the result revealed from the addition of isoniazid (INH) 
in dose of 100 µg/ml – 200 µg/ml, furtherly contracted the 
adrenaline stimulated isolated rabbit aortic strip. The effects of 
both adrenaline and INH were inhibited by tolazoline in a dose 
10µg/ml. This indicates that INH may potentiate the effect of 
adrenaline. 
  
As the experiment showed in the isolated rat was 
deference, INH in a dose of up to 2 µg/ml was without effect but 
when administrated in a dose 500 µg/ml slightly potentiated the 
effect of adrenaline in a dose of 1µg/ml. 
Chloroquine phosphate when added in a dose of 800 
mg/ml to the isolated rabbit aortic strip in presence of adrenaline 
showed insignificant contraction and this effect was blocked by 
tolazoline and atenolol. 
However, quinine when added in different doses to the 
isolated rabbit aortic strip: in presence of adrenaline showed no 
significant effect. Also quinine when added in presence of 
propranolol to the insitu frog heart showed no significant effect 
the on heart peaks. 
As the study revealed, the p-blockers; propranolol and/or 
atenolol don't show significant interactions when combined with 
chemotherapeutic agents like isoniazid, chloroquine and quinine. 
 
 
 
   
 
 
 
 
  
  ﻤﻠﺨﺹ ﺍﻷﻁـﺭﻭﺤﺔ
  
 
ﻓﻰ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺘﻡ ﺍﺴﺘﻘﺼﺎﺀ ﺍﻟﺘﻔﺎﻋﻼﺕ ﺍﻟﺩﻭﺍﺌﻴﺔ ﺍﻟﺩﻴﻨﺎﻤﻴﻜﻴﺔ ﺒﻴﻥ ﺒﻌﺽ ﺃﺩﻭﻴﺔ ﺤﺎﺼﺭﺍﺕ 
ﺃﻫﻤﻴﺔ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺘﻨﺒﻊ ﻤﻥ ﺍﻥ ﺒﻌﺽ ﻤﺭﻀﻰ ﺍﻟﺠﻬﺎﺯ ﺍﻟﻘﻠﻴﻰ .  ﻭﺍﺩﻭﻴﺔ ﺍﻟﻤﻌﺎﻟﺠﺔ ﺍﻟﻜﻴﻤﺎﺌﺒﺔ( ﺒﻴﺘﺎ)
ﺩﺭﻥ ﺍﻟﺭﺌﻭﻯ،  ﺍﻟﻤﻼﺭﻴﺎ، ﺍﻟﻠﻴﺸﻤﺎﻨﻴﺎ ﻭﺍﻟ-:ﺍﻟﻭﻋﺎﺌﻰ ﻴﻜﻭﻨﻭﺍ ﻤﺼﺎﺒﻴﻥ ﺒﺄﻤﺭﺍﺽ ﺍﻟﻤﻨﺎﻁﻕ ﺍﻟﺤﺎﺭﺓ ﻤﺜل
  .ﺤﻴﺙ ﺍﻥ ﺍﻟﺴﻭﺩﺍﻥ ﻴﻌﺘﺒﺭ ﻤﻥ ﺍﻟﻤﻨﺎﻁﻕ ﺍﻻﺴﺘﻭﺍﺌﻴﺔ ﺍﻟﺤﺎﺭﺓ
  -:ﺍﻟﺘﻰ ﺘﻡ ﺍﺨﺘﻴﺎﺭﻫﺎ ﻟﻬﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻫﻰ( ﺒﻴﺘﺎ)ﺤﺎﺼﺭﺍﺕ 
  .ﺒﺭﺒﺭﺍﻨﻭﻟﻭل ﻫﺎﻴﺩﺭﻭﻜﻠﻭﺭﺍﻴﺩ -1
 .ﺍﺘﻴﻨﻭﻟﻭل -2
  -:ﺃﻤﺎ ﺍﺩﻭﻴﺔ ﺍﻟﻤﻌﺎﻟﺠﺔ ﺍﻟﻜﻴﻤﻴﺎﺌﺒﺔ ﺍﻟﻤﺨﺘﺎﺭﺓ ﻭﻫﻰ
  .ﻜﻠﻭﺭﻭﻜﻭﻴﻥ ﻓﻭﺴﻔﺎﺕ -1
 .ﻜﻴﻨﻴﻥ ﺜﻨﺎﺌﻰ ﺍﻟﻬﺎﻴﺩﺭﻭﻜﻠﻭﺭﺍﻴﺩ -2
 .ﺍﻴﺯﻭﻨﻴﺎﺯﻴﺩ -3
  -: ﻤﻥ ﺍﻟﻨﻤﺎﺫﺝ ﺍﻟﻔﺎﺭﻤﺎﻜﻭﻟﻭﺠﻴﺔﻋﻠﻰ ﺜﻼﺜﺔ ﺩﺭﺍﺴﺔ ﻫﺫﻩ ﺍﻟﺘﻔﺎﻋﻼﺕ ﻭﺘﻤﺕ
  (.utis nI)ﻗﻠﺏ ﺍﻟﻀﻔﺩﻉ  -1
 .ﺸﺭﻴﻁ ﺍﻟﺸﺭﻴﺎﻥ ﺍﻻﺒﻬﺭ ﺍﻟﻤﻌﺯﻭل ﻤﻥ ﺍﻻﺭﻨﺏ -2
 .ﺍﻟﻘﻨﺎﺓ ﺍﻟﺩﺍﻓﻘﺔ ﺍﻟﻤﻌﺯﻭﻟﺔ ﻤﻥ ﺍﻟﻔﺄﺭ -3
 – lm/gµ001 ﺒﺠﺭﻋﺔ ﺘﺴﺎﻭﻯ  HNI ـﻋﻨﺩ ﺍﻀﺎﻓﺔ ﺍﻟ ﺤﺴﺏ ﻤﺎ ﺃﻅﻬﺭﺕ ﺍﻟﺘﺠﺎﺭﺏ ﺯﺫﻟﻙ 
ﺍﻟﻰ ﺸﺭﻴﻁ ( ﺘﻭﻻﺯﻭﻻﻴﻥ+ ﺍﺘﻨﻭﻟﻭل + ﺍﻻﺩﺭﻴﻨﺎﻟﻴﻥ  ) ﻓﻰ ﻭﺠﻭﺩ ﺃﺩﻯ ﺫﻟﻙ ﺇﻟﻰ     lm/gµ 002
ﻭﻫﺫﺍ .  ﺍﻻﺒﻬﺭ ﺍﻟﻤﻌﺯﻭل ﻤﻥ ﺍﻻﺭﻨﺏ ﻗﺩ ﺍﺩﻯ ﺍﻟﻰ ﺍﻨﻘﺒﺎﺽ ﺍﻟﺸﺭﻴﺎﻥ ﺍﻻﺒﻬﺭ ﻜﻠﻤﺎ ﺯﺍﺩﺕ ﺍﻟﺠﺭﻋﺔ
 ﺍﻟﻰ ﻗﻠﺏ ﺍﻟﻀﻔﺩﻉ HNIﻭﻋﻨﺩ ﺍﻀﺎﻓﺔ ﺍل  (.  ﺍﻟﻔﺎ) ﻟﻤﺴﺘﻘﺒﻼﺕ ﻔﺯ ﻴﻌﻤل ﻜﻤﺤHNI ـﻌﻨﻰ ﺃﻥ ﺍﻟﻴ
  
ﺍﻟﻜﻠﻭﺭﻜﻴﻥ ﺍﻟﻰ ﺍﻟﺸﺭﻴﺎﻥ ﺍﻻﺒﻬﺭ ﺍﻟﻤﻌﺯﻭل ﻭﻋﻨﺩ ﺍﻀﺎﻏﺔ . ﻗﺩ ﺍﺩﻯ ﺍﻟﻰ ﺯﻴﺎﺩﺓ ﻗﻭﺓ ﺍﻨﻔﺒﺎﺽ ﺍﻟﻘﻠﺏ
ﻤﻥ ﺍﻻﺭﻨﺏ ﻓﻰ ﻭﺠﻭﺩ ﺍﻻﺩﺭﻴﻨﺎﻟﻴﻥ ﺍﺩﻯ ﺍﻟﻰ ﺯﺒﺎﺩﺓ ﺍﻨﻘﺒﺎﺽ ﺍﻟﻘﻠﺏ ﺒﺼﻭﺭﺓ ﻴﻌﺘﺩ ﺒﻬﺎ ﺍﺤﺼﺎﺌﻴﺎ ﻭﻫﺫﺍ 
ﺍﻷﺘﺭ ﺘﻡ ﺤﺼﺭﻩ ﺒﺄﻀﺎﻓﺔ ﺍﻷﻨﻴﻨﻭﻟﻭل ﻭ ﺍﻟﺘﻭﻻﺯﻭﻟﻴﻥ ﻭﻫﺫﺍ ﻴﺩل ﻋﻠﻰ ﺃﻥ ﺍﻟﻜﻠﻭﺭﻜﻭﻴﻥ ﻗﺩ ﺒﻌﻤل ﻋﻠﻰ 
  (.ﺍﻟﻔﺎ)ﻭ ( ﺒﻴﺘﺎ)ﺘﻨﺸﻴﻁ ﻤﺴﺘﻘﺒﻼﺕ 
( ﻓﻰ ﻭﺠﻭﺩ ﺍﻷﺩﺭﻴﻨﺎﻟﻴﻥ) ﺍﻟﻰ ﺍﻟﺸﺭﻴﺎﻥ ﺍﻷﺒﻬﺭ ﺍﻟﻤﻌﺯﻭل ﻤﻥ ﺍﻻﺭﻨﺏ ﻋﻨﺩ ﺍﻀﺎﻓﺔ ﺍﻟﻜﻴﻨﻴﻥ
 ﺍﻻﻨﻘﺒﺎﺽ ﻻﻴﻌﺘﺩ ﺒﻬﺎ ﻭﻜﺫﻟﻙ ﻋﻨﺩ ﺍﻀﺎﻓﺔ ﺍﻟﻜﻴﻨﻴﻥ ﺍﻟﻰ ﻗﻠﺏ ﺍﻟﻀﻔﺩﻉ ﻟﻡ ﻴﺤﺩﺙ ﻓﻰﺃﺩﻯ ﺍﻟﻰ ﺯﻴﺎﺩﺓ 
  .ﺘﺄﺜﻴﺭﺍ ﻤﻠﺤﻭﻅﺎ
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 1
CHAPTER ONE 
 INTRODUCTION AND LITERATURE REVIEW  
 
β- adrenoceptor antagonists (β-blockers) are widely prescribed 
for the treatment of common diseases such as hypertension and angina 
pectoris in which they are often used concurrently with other drugs and 
given to patients taking a variety of medicines for other purposes. 
However, despite the fact that β-blockers are known to interact with a 
number of other drugs, there has been little evidence to suggest that most 
of these interactions are clinically important. An interaction can occur 
either by pharmacodynamic or by pharmacokinetic mechanisms, and it 
can affect either the β-blocker or the other drug or both (Denis, 1988).   
Pharmacodynamic interactions involving β-blockers may modify 
the therapeutic actions of the β-blocker or the other drug, or they may 
increase the adverse effects of the β-blocker (Denis, 1988).   
The antihypertensive effect of  β-blockers may be impaired by 
the concurrent administration of some non-steroidal anti-inflammatory 
drugs (NSAIDs), possibly due to their inhibition of the synthesis of renal 
vasodilator prostaglandins. Increases in mean arterial blood pressure of 
up to 15mm Hg have followed the administration of indomethacin to 
treated hypertensive patients. This interaction probably common to all β-
 2
blocker, but may not occur with all NSAIDs-for example sulindac, which 
inhibit the systemic but not the renal synthesis of prostaglandins, appears 
to affect blood pressure control less than indomethacin. This is a 
potentially important, relatively common and large unrecognized drug 
interaction (Denis, 1988). 
Non-selective β-blockers, even those with partial agonistic 
activity, antagonize the bronchodilator response to β2-agonists (e.g. 
salbutamol and terbutaline) in patients with reversible obstructive airways 
disease. Contrarly to popularly held belief, β-selective blockers (e.g. 
metoprolol, atenolol), also result in some reduction in β-agonist-induced 
bronchodilaiation (Denis, 1988).  
One of the factors that can alter the response to drugs is the 
concurrent administration of other drugs. There are several mechanisms 
in which drugs may interact, but most can be categorized as 
pharmacokinetic (absorption, distribution, metabolism and excretion), 
pharmacodynamic, or combined interactions. Knowledge of the 
mechanism by which a given drug interaction occurs is often clinically 
useful, since the mechanism may influence both the time course and the 
methods of circumventing the interaction. Some important drug 
interactions occur as a result of two or more mechanism (Katzung, 2001).  
 
 3
Pharmacokinetic mechanism:  
The gastrointestinal absorption of drugs may be affected by 
concurrent use of other agents that:  
• Have a large surface area upon which the drug can be absorbed. 
• Bind or chelate. 
• Alter gastric pH.   
• Alter gastrointestinal mortality. 
• Affect transport proteins such as P. glycoprotein. 
 One must distinguish between effects on absorption rate and 
effects on extent of absorption. 
A reduction in the absorption rate of a drug is seldom clinically 
important whereas a reduction in the extent of absorption will be 
clinically important it results in subtherapeutic serum levels. 
The mechanisms by which drug interactions affect drug 
distribution include:  
- Competition for plasma protein binding.  
- Displacement from tissue binding sites.  
The metabolism of drugs can be stimulated or inhibited by 
concurrent therapy of drug inducer or inhibitor. Induction of cytochrome 
isozymes in the liver and small intestine can be caused by drugs such as 
barbiturate, carbamazepine, phenytoin and troglitazone (Katzung, 2001). 
 4
Enzyme inducers can also increase the activity of phase II 
metabolism such as glucuronidation. Enzyme induction doesn’t take 
place quickly, maximal effects usually occur after 7-10 days and require 
an equal or longer time to dissipate after enzyme inducers is stopped. 
Drugs that may inhibit hepatic microsomal metabolism of other drugs 
include allopurinol, amiodarone cimitidine, ciprofloxacin, ketoconazole, 
grapefruit juice, fluoxetine and metronidazole (Katzung, 2001).  
The renal excretion of active drug can also be affected by 
concurrent drug therapy. The renal excretion of certain drugs that are 
weak acids or weak bases may be influenced by other drugs that affect 
urinary pH. This is due to changes in ionization of the drug.  
The Henderson-Hasselbalch equation relates the ratio of 
protonated to unprotonated weak acid or weak base to the molecule’s pKa 
and the pH of medium as follows:  
Log  (Protonated) = Pka – pH 
      (Unprotonated) 
 
For some drug active secretion into the renal tubule is an 
important elimination pathway. This process may be affected by 
concurrent drug therapy, thus altering serum drug levels and 
pharmacologic response (Ktzung, 2001).   
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Pharmacodynamic mechanisms:  
When drugs with similar pharmacologic effects are administered 
concurrently, additive or synergistic response is usually seen. The two 
drugs may or may not act on the same receptor to produce such effects. 
Conversely, drugs with opposing pharmacologic effects may reduce the 
response to one or both drugs.  
Pharmacodynamic drug interactions are relatively common in 
clinical practice, but adverse effects can usually be minimized if the 
interactions are anticipated and appropriate counter measures taken 
(Katzung, 2001).  
Important drug interactions:  
Properties promoting drug interaction: for beta-adrenoceptor. 
1-Blockers:  (especially with non selective agents such as proparanolol) 
alter response to sympathomimetics with B-agonistic activity, e.g. 
epinephrine.  
Beta-blockers that undergo extensive first pass metabolism may 
be affected by drugs capable of altering this process. Beta blockers may 
reduce hepatic blood flow. 
Drugs that may increase B-blocker effect cimtidine decrease the 
metabolism of B-blockers that are cleared primarily by the liver e.g. 
propranolol.  
 6
Less effect (if any) on those cleared by the kidney, e.g. atenolol. 
Furosemide and hydralazine decreased metabolism of propranolol.  
Drugs that may decrease B-blocker effect:  
• Enzyme inducer, e.g. barbiturate, rifampicin.  
• Nonsteridol anti-inflammatory drugs, e.g. indomethacin.  
Effect of B-blockers on other drugs:  
Insulin: inhibition of glucose recovery from hypoglycemia and 
symptoms of hypoglycemia and increased blood pressure during 
hypoglycemia. 
Prazosin: Increased hypotensive response to first dose of 
prasozin (Ktzung, 2001).   
2-Chloroquine: With gold and phenylbutazone in the treatment of 
rheumatoid arthritis may exacerbate dermatitis produced by those drugs. 
It has quinidine-like effect since it cause electrocardio-graphic changes. 
Patients with psoriasis or porphyria shouldn’t be treated with 
chloroquine because an acute attack may be provoked, and should be 
used cautiously in patient with hepatic dysfunction, severe 
gastrointestinal problems, neurologic and blood disorders (Mary, et al. 
2000).  
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3- Quinine:  
• With aluminium containing anti-acid retard the 
absorption.  
• With diagoxin elevate its level.  
• Potentiation of neuromuscular blocking agent.  
• Quinine should be suspended if a positive result to a Coombs’ test for 
haemolytic anemia occurs.     
4- Isoniazid (INH):    
Can potentiate the adverse effect of phenytoin (e.g. nystagmus, ataxia 
because INH inhinit metabolism of phenytion. Slow acetylators are 
particularly at risk (Champe, et al, 2000).   
5- Atenolol:  
Atenolol is a β1-receptor blocker used in the treatment of arterial 
hypertension, coronary heart disease, and cardiac arrhythmias. Thus 
under these circumstances, beta-blockers may be combine with other 
drugs that may have to be administered concurrently for other reasons. 
For example, allopurinol may be given to treat hyperuricemia and 
ampicillin for treatment of infections disease. Aspirin is often use as 
analgesic and for prophylaxis of shunt thrombosis in patient undergoing 
long term intermittent haemodialysis.  
 8
In recent reports on atenolol kinetics in renal failure and on the 
interactions of atenolol it was found that calcium (and also alumirium 
hydroxide) had an effect on atenolol kinetic where as frusemide didn’t 
(Kirch, et al 1981). Ampicillin has been shown to intensify the effects of 
coumarins anti-coagulants (Kabins, 1972; Koch et al, 1971). Aspirin 
raises plasma levels of indomethacin and impairs renal excretion of 
nitrofurantion (Yeasair, et al, 1972; Huller et al 1975).   
In study correlate interaction of atenolol with aspirin, alloparinal 
and ampicillin after single oral dose (100 mg) and long term oral to the 
anti-hypertensive effect of atenolol, combination therapy with ampicillin 
requires close clinical control of the treated patients, since 12hr after the 
last dose of atenolol  and ampicillin blood pressure values during exercise 
increase over those after atenolol alone. In patient at rest however during 
4 week treatments there are no differences in pressure values between the 
monotherapy and the combined treatment phases. Thus it may be 
necessary to double the atenolol dose during combination therapy with 
ampicillin in order to achieve the descried anti-hypertensive effect. If 
atenolol is used for treatment of patient with angina pectoris, the dose of 
atenolol certainly has to be doubled during the period of combination 
therapy. This therapeutic implication is significant since it may 
sometimes happen that patient who have to be treated with atenolol might 
 9
be treated simultaneously with ampicillin for an infections disease 
(Monika et al, 1982).     
Concomitant administration of lariam and quinine, quinidine or 
drugs producing beta-adrenergic blockade may produce 
electrocardiographic abnormalities or cardiac arrest. Concomitant 
administration of lariam and quinine or chloroquine may increase the risk 
of convulsion (Reith, et al, 1996).  
Beta-blockers that are lipid soluble and have marked anti-
arrhythmic (i.e. quinidine like effects) are more lethal e.g. propranolol, 
sotalol). Between 1985 and 1995 71% of fatalities reported to the 
American Association of Poison Control Centers (AAPCC) were caused 
by propranolol, despite being responsible for 44% of exposures.  
Internationally: propranolol is the most toxic beta-blockers and 
the most frequently used in suicide attempts worldwide (Brett, et al, 
2005).  
PROBLEM RELATE TO TROPICAL DISEASES:  
The most important tropical diseases in the Sudan are malaria, 
tuberculosis, leishmaniasis and Gardiasis. Malaria can exacerbate pre-
existing clinical conditions, adding to its morbidity and mortality.  
Pre-existing cardiovascular obstruction, compromised ventricular 
function and other condition of cardiac decompensation may land in 
trouble on contracting malaria. In severe Falciprum malaria, the 
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myocardial function is remarkably maintained and most patient have an 
elevated cardiac index, with low systemic vascular resistance and low to 
normal right and left sided filling pressures. However in patient with 
decompensated heart the high grade fever, tachycardiac,  hypoxemia, 
metabolic acidosis …etc.. associated with malaria may add to the existing 
cardiac decompensation. 
Pre-existing anemia: Anemia is a common problem in developing 
countries of Africa and Asia and is commonly due to helminthiasis and 
malnutrition. Both Vivax and Falciparum malaria can exacerbate the 
anemia, specially causing problems in pregnancy and in children. Also, 
blood transfusion for anemia may transmit malaria.  
Pre-existing renal disease: Severe falciparum can compromise 
renal blood flow by sequestration and obstruction to the microcirculation, 
by haemolysis, by dehydration and hypovolumia, by acidosis ….etc. The 
dose of quinine needs modification in renal failure whenever serum 
creatinine is >3 mg %. Chloroquine increase plasma cyclosporin 
concentration and may increase the risk of toxicity (Staff of Medicine 
Information, 1998).  
Pre-existing liver disease:  
Patient with hepatocellular failure due to cirrhosis etc… may 
deteriorate of the contract malaria. A case of malaria in recipient of 
orthotopic liver transplantation has been reported. The infection was trace 
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to a platelet transfusion and responded to treatment with chloroquine. 
Risk factors associated with the development of malaria infection are 
identifiable and should be reviewed from the recipient and donor when 
possible (Talabiska, et al, 1996).  
None of the anti-malarial drugs have any direct hepatotoxic 
effect. However, chloroquine is not advisable in patients with severe 
hepatic insufficiency. Pre-existing C.N.S disease: Malaria and anti-
malarial drugs may cause problems in patients with per-existing C.N.S 
disorder like dementia, epilepsy. Severe falciparum infection, 
dehydration, hyponatremia, high grade fever can lead to deterioration of 
patient have pre-existing dementia and may be prone for secondary 
infection like aspiration bronchopneumonia. Chloroquine, quinine and 
mefloquine can cause neurosychiatric effects (Staff of Medicine 
Information, 1998).  
Epilepsy:  
There are some reports of chloroquine causing convulsions even 
in previously healthy patients. Mefloquine is contraindicated in patients 
with a history of convulsions. First-time seizures in patients taking 
mefloquine in prophylactic doses have been reported. Mefloquine 
acerbating the hepatic metabolism of sodium valproate, because they are 
both metabolized by the same hepatic enzyme system. Epileptic patients 
not taking carbamazepine, pherytion and barbiturates can safely use 
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doxycycline as malaria prophylaxis. Doxyacyline interact with some 
anticonvulsant by liver enzyme induction (Staff of Medicine Information, 
1998).  
Diabetes mellitus: Severe P. falciparium malaria can cause 
hypoglycemia and this fact should be borne in mind in diabetic receiving 
insulin or oral hypoglycemic agents: suitable dosage adjustments may be 
needed.  
Quinine has stimulatory effects on the pancreatic beta cells and is 
known to cause severe hypoglycemia. Thereby, it may potentiate the 
effects of sulfonylurea. In normal patients and normal doses chloroquine 
doesn’t appear to cause increased pancreatic secretion of insulin and has 
no effect on plasma glucose concentration (Staff of Medicine 
Information, 1998). 
Myasthenia gravis: quinine decreases the excitability of the motor 
endplate region so that response to repetitive nerve stimulation and to 
acetylcholine is reduced; also produce alarming respiratory distress and 
dysphagia in patients with myasthenia gravis. 
Chloroquine also may increase the symptom of myasthenia gravis 
and reduce the effect of neostigmine and pyridostigmine.  
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TESTED DRUGS: 
The following drugs were selected for the previous study: 
1-β – (Adrenceptor) adrenergic blocking agent: 
All the clinically available β-blockers are competitive antagonist. 
Non selective β-Blocker act at both β 1 & β 2 receptors e.g. propanolol 
where as cardio selective β-antagonists primarily block β 1- receptors e.g. 
atenolol. These drugs also differ in intrinsic sympathominetic activity, in 
central nervous system effects and in pharmacokinetics, although all             
β-blocker lower blood pressure in hypertension, they don’t induce 
postural hypotension because the α-adrenoceptors remain functional, 
therefore normal sympathomimetic control of the vasculature is 
maintained (Richard, et al, 2000). 
Pharmacokinetic Properties of the β-Receptor Antagonists: 
Most of the drugs in this class are well absorbed after oral 
administration, peak concentration occur 1-3 hours after ingestion. 
Propraolol undergoes extensive hepatic metabolism (First pass effect).   
It’s bioavailability is relatively low due to oral administration of the drugs 
leads to much lower drug concentration than are achieved after 
intravenous injection of the same dose, because the first-pass effect varies 
among individuals, there is a great individual variability in the plasma 
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concentrations achieved after oral propranolol administration (Bertam, 
2001). 
The β-antagonists are rapidly distributed and have large volumes 
of distribution. Propranolol is quite lipophilic and readily crosses the 
blood brain barrier.  Most β-antagonist have half-life in the range of 3 -10 
hours.  A major exception is atenolol, which is rapidly hydrolyzed and 
has a half life of approximately 10 minutes. Propranolal is extensively 
metabolized in the liver with little unchanged drug appearing in the urine. 
Atenolol less completely metabolized. Propranolol is the proto type            
β-blocking drug for both β 1 & β 2 receptors.  It has low and dose 
dependent bioavailability. The drug has negligible effect at α and 
muscarinic receptors, however it may blocks some serotonin receptors in 
the brain, through the clinical significance is unclear.  It has no detectable 
partial agonist action at β-receptors (Bertam, 2001). 
Propranolol: 
 Actions: 
a- Cardiovascular: Diminishes cardiac out put, having both negative 
inoropic and chronotropic effects.  It directly depresses sinoatrial and 
a ventricular activity.  The resulting bradycardia usually limits the 
does of the drug, where cardiac output, work, and oxygen 
consumption are decreased. These effects are useful in the treatment 
of angina.  The β-blockers are effective in attenuating supraventricular 
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cardiac arrhythmias but are generally not effective against ventricular 
arrhythmias. 
b- Peripheral vasoconstriction: Blockade of β-receptors prevents β2-
mediated vasodilatation.  The reduction in cardiac output leads to 
decrease blood pressure and this hypotension triggers a reflex 
peripheral vasoconstriction which is reflected in reduces blood flow to 
the periphery.  On balance there is a gradual reduction of both systolic 
and diastolic blood pressure in hypertensive patients and no postural 
hypotension occurs, since the α1-adrenergic receptors that control 
vascuolar resistance are unaffected. 
c- Bronchoconstriction: Blocking β2- receptors in the lung causes 
contraction of the bronchiolar smooth muscle and this can precipitate 
a respiratory crisis in patient's with chronic obstructive pulmonary 
disease or asthma, so β-blockers contraindicated in patient with 
asthma. 
d- Increased sodium retention: Reduce blood pressure causes a 
decrease in renal perfusion resulting in an increase in sodium retention 
and plasma volume so β-blockade are combined with a diuretic to 
prevent sodium -retention. 
e- Disturbance in glucose metabolism: β-blockade leads to decreased 
glycogenolysis and decreased glucagon secretion.  Since pronounced 
hypoglycemia may occur after insulin injection, very careful 
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monitoring of blood glucose is essential in an insulin dependent 
diabetic who is to be given porpranolol. Also β-blockers attenuate the 
normal physiologic response to hypoglycemia. 
f- Blocks action of isoproterenol: All β-blockers including propronolol 
have the ability to block the action of isoproterenol on the 
cardiovascular system.  This isoproterenol dose not produces either 
typical reductions in mean arterial pressure and diastolic pressure. 
Therapeutic uses of propranolol: 
a- Hypertension. 
b- Angina Pectaris. 
c- Myocardial infarction. 
d- Arrythmias. 
e- Cardiomyopathy  
f- Vascular surgery. 
g- Glaucoma. 
h- Migraine. 
i- Anxiety 
j- Hyperthyroidism. 
k- Pheochromocytoma.  
l- To reduce tremor in Parkinsonism.  
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Adverse effects include: 
a- Broncho- constriction. 
b- Bradycardia. 
c- Sexual impairment. 
d- Disturbance in metabolism. 
e- Increase peripheral vascular resistance.  
f- Hypotension.  
g- Heart failure or heart block. 
Drug interaction: 
Drugs that interfere with the metabolism of propronolol, such as 
cimetidine, Furosemide and chloropromazine may potentiate its anti-
hypertensive effects.  Conversely, those that stimulate its metabolism, 
such as barbiturates, phenytoin and rifampicin can decrease its effects. 
(Ritchard, 2000). 
Atenolol(Selective β1-anagonist): 
Drugs that preferentially block the β1-receptors have been 
developed to eliminate the unwanted bronchoconstrictor effect of β2 of 
propranolol seen among asthmatic patient. 
Atenolol antagonizes β1- receptor at doses 50 to 100 timeless than 
those required to block β2-receptors. This cardio selectivity is thus most 
pronounced at low doses and is lost at high drug doses. 
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Actions: 
The drug lowers blood pressure in hypertension and increase 
exercise tolerance in angina.  In contrast to propranolol, the cardio 
specific blockers atenolol has relatively little effect on pulmonary 
function, peripheral resistance and carbohydrate metabolism. 
Therapeutic uses: 
1- In hypertensive patients with impaired pulmonary function. 
2- Useful in diabetic hypertensive patients who are receiving insulin or      
oral  hypoglycaemic agents (Richard, 2000).  
Isoniazid  (INH): 
The hydrazide of isonicotinic acid is a synthetic analogue of 
pyrodoxine.  It is the potent anti tubercular drug, but is never given as a 
single agent in the treatment of active tuberculosis. 
1- Pharmacokinetic: The drug is readily absorbed orally but impaired if 
taken with food, particularly carbohydrates or with aluminum 
containing anti-acids. INH diffuses into all body fluid, cells and 
caseous materials (necrotic tissue resembling cheese), the level in the 
cerebrospinal fluid (CSF) are about the same as those in the serum.  
Infected tissues tend to retain the drug longer. The drug readily 
penetrates host cells and is effective against bacilli growing 
intracellularly. INH under goes N-acetylation and hydrolysis is 
resulting in inactive products.  Acetylation is genetically regulated, the 
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fast acetylator trait is autosomally dominant.  A bimodal distribution 
of fast & slow acetylators exists. Excretion is through glomerular 
filtration, predominantly as metabolites.  Slow acetylators excrete 
more of the parent compound.  The drug is also excreted into the 
saliva, sputum and milk. Chronic liver disease will decrease 
metabolism and doses must be reduced.  Severally depressed renal 
function result in accumulation of the drug primarily in slow 
acetylators. 
 Mechanism of action: 
INH is believed to target the enzyme responsible for assembly 
of mycolic acids into the outer layer of the mycobacteria, structure unique 
to those organism mycolicacids account for the acid fastness of the 
mycobateria, this property is lost after exposure to INH. 
Anti-bacterial spectrum: 
For bacilli in the stationary phase, the drug is bacteriostatic, but 
for rapidly dividing organisms, it is bacteriocidal.  It is effective against 
intracellular bacteria.  
Resistance: 
Is associated with the constitutive inability of organism to 
accumulate the drug, also that the target enzyme may be altered so as not 
bind INH or that excessive amount of the enzyme may be produced so 
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that the drug is overwhelmed.  No cross resistance exist between INH and 
other anti tubercular drugs. 
 Therapeutic uses:   
INH is specific for treatment of M. tuberculosis. Although 
Mycobacterium  kansasi may be susceptible at higher drug levels.  When 
it is used alone resistance organism rapidly emerged. 
Adverse effect: 
a- Peripheral neuritis. 
b- Hepatitis and idiosyncratic hepatotoxicity. 
Other adverse effect includes mental abnormality, convulsions in 
patient prone to seizures, and optic neuritis.  Hypersensitivity reactions 
include rashes and fever (Pamela, et al, 2000). 
Drug interaction: 
INH can potentiate the adverse effects of phenytoin (e.g. 
nystagmus, ataxia) because the INH inhibits its metabolism.  Slow 
acetylators are particularly at risk. 
1- Quinine (Qne): 
Quinine is a blood schizontocide with activity against                         
P. falciparum, P. vivax, P. ovale and P. malariae. It is active against the 
gametocytes of P. malariae, P. vivax, but not P. falciparum. Since it has 
no activity against exoerthrocytic forms, quinine does not produce a 
radical cure in Vivax ovale infection.  
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Quinine passes through the stomach and completely absorbed 
from the upper intestine. It is quickly metabolized by the tissues or 
excreted uncharged in urine. Peak plasma concentration is reached 1-3 
hour after a single oral dose.  
Quinine owe side effects of which one giddiness, ringing in the 
ear, fermors and blurred vision. It is very fatal when given via 
intravenous route. So it is very safe when given in a drip of sodium 
chloride. Salts of quinine if common use are: sulfate, bisulfate, 
hydrochloride and dihydrochloride (Bruce, 1986).    
2- Chloroquine (CQ): 
Chloroquine belongs chemically to the 4-aminoguinoline group. 
Chloroquine is a very potent schizonticidal drug. It is effective against 
erythrocytic forms of all four plasmodium species. This not effective on 
sporozoites, hypnozoites or gametocytes. It is a weak base but its 
accumulation in the parasite lysosome is 1000-fold greater than in 
predicted this basis (Rang, et al, 1999).  
Mechanism of action:  
 Chloroquine inhibits digestion of haemoglobin by the parasite 
and this reduce the supply of aminoacids necessary for the parasite 
viability. It also inhibit haem polymerase. The enzyme that polymerises 
toxic free haem to haemozoin, rendering it harmless (Rang, et al, 1999).  
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Plasmodium flaciparum is now resistant to chloroquine in most 
parts of the world. Resistance appears to be due to increased efflux of the 
drug from parasite vesicles and/or decreased uptake. There are also 
reports of Plasmodium vivax resistance to chloroquine in some areas 
(Rang, et al, 1999).  
Clinical uses:  
Chloroquine is used for the treatment of: 
a. Malaria.  
b. Remission of rheumatoid arthritis.  
c. Systemic and discoid lupus erythrematosus.  
Administration and pharmacokinetic aspects:  
Chloroquine when given orally, is completely absorbed, is 
extensively distributed throughout the tissues and is concentrated in 
parasitized red cells. In severe Plasmodium it is given via frequent 
intramuscular injections or by slow continuous infusion.  
 Chloroquine is metabolized in the liver. It is excreted in urine, 
70% as unchanged drug and 30% as metabolites. Elimination is slow, the 
major phase having a half-life of 50 hours and residue persists for weeks 
or months.  
Adverse effects:  
Chloroquine has few adverse effects when given to 
chemoprophylaxis. With larger doses used to treat malarial attack, 
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unwanted effects occasionally occur include vomiting, dizziness, blurred 
vision, headache and urticarial symptoms. Large doses of chloroquine can 
result in retinopathies. Bolus intravenous injections of chloroquine can 
cause hypotension (Rang, et al, 1999).  
Introduction to some of the chronic diseases: 
1- Hypertension:   
Hypertension is the most common health problem, yet it is not a 
disease, it has no symptoms and patient does not die form it. Its 
importance lies in that, it is the major risk factor for cerebrovascular 
accidents and cardiovascular events (Roger, et al, 1999).  
The world health organization defines hypertension as a diastolic 
blood pressure reading greater than 95 mmHg, on more than one 
occasion. Diastolic blood pressure readings between 90 and 95 mmHg are 
described as mild or borderline. Raised systolic blood pressure can exist 
in the absence of raised diastolic blood pressure and therefore, systolic 
blood pressure greater than 160 mm Hg are also classed as hypertensive.  
Epidemiology:  
Hypertension occurs in 10-20% of middle-aged adults in 
developed countries and become more common with increasing age. 
Primary hypertension accounts for approximately 95% of the 
hypertensive population, the remainder consisting of patients with 
secondary hypertension (Roger, et al 1999).  
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Factors affecting primary hypertension are:  
• Age.  
• Genetics.  
• Environment: e.g. stress, sodium intake and alcohol.  
• Weight.  
• Race.             
Secondary hypertension:  
Secondary hypertension has an identifiable underlying cause. 
However, removing the cause will necessarily result in blood pressure. 
This is because the raised blood can damage organs such as the kidneys, 
which creates a vicious cycle by causing a further rise in blood pressure 
and leads to more damage (Roger, et al, 1999).  
Some common causes of secondary hypertension are:  
• Renal disease (polycystic kidneys, renal artery stenosis, pyelonephritis 
and renal tumour). 
• Drug induced (oral contraceptives, carbenoxolone and liqurices 
derivatives and corticosteroids).  
• Pregnancy (incase of pre-eclampsia).  
• Hormonal causes like Cushing’s syndrome, pheacochromocytoma and 
acromegaly) (Roger, 1999).  
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Drug treatment:  
The British hypertensive society currently recommends a 
stepwise approach to treatment of essential hypertension starting with a 
diuretic, then a β-adrenoreceptor blocker, then a combination of the two, 
with addition of a vasodilator if the combination is not effective.  
It is probably more appropriate to approach drug therapy from a 
point of view of the patient and his or her concomitant disease state. 
However, in order to do so, some knowledge of the mode of action of 
various classes of drugs is essential (Roger, et al 1999).  
A) Diuretics:  
• Thiaizedes: are the commonest group of diuretics used in the treatment 
of hypertension. Loop durietics are occasionally used but appear to have 
a smaller hypertensive effect than thiazides, but are useful in patients 
with renal impairment and when the patient requires a more potent 
diuresis in heart failure. The potassium sparing diuretics are used in 
combination with loop or thiazides diuretics to prevent hypokalemia 
(Roger, et al 1999).  
B) Beta-blockers:  
 The most common β-adrenoceptors blockers used in 
hypertension are propranolol (non-selective) and atenolol (cardio-
selective).  
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C) ACE-inhibitors:  
These drugs act by blocking the conversion of angiotension I to 
angiotensin II and so prevent the vasoconstrictive effect of angiotensin II. 
Example of this class are captopril, enalapril and lisonpril.  
D) Calcium channel blockers:  
 These act by blocking the calcium channels in the smooth 
muscle, hence reducing or preventing muscle contraction. There as 
though to be at least 3-different receptor sites where they act and different 
types of calcium channel blockers show different effects, for example on 
heart rate and peripheral vasodilatation. The dihydropyridines (for 
example nifedipine and amlodipine) have relatively little direct effect on 
the heart compared with phenylalkylamines (for example diltiazen) 
(Roger, et al, 1999).  
2- Diabetes mellitus:  
Diabetes mellitus is a heterogeneous group of disorder, 
characterized by varying degree of insulin hyposecretion and/or insulin 
insensitivity. Regardless of cause, it is associated with hyperglycaemia 
(Roger, et al, 1999).  
Types of diabetes mellitus:  
• Insulin dependent diabetes mellitus (IDDM): there are major ethnic 
and geographical differences in the prevalence and incidence of IDDM. 
It is highest in Caucasians whilst the disorder is rare in the Japanese and 
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in pacific. In Northern Europe the prevalence is increasing, it is 
approximately 0.3% in those under 30 years of age. 
• Non-insulin-dependent diabetes mellitus (NIDDM): it is much 
encounter than IDDM, accounting for 75 to 95% of diabetes in most 
populations. It is usually occurs in patients over 40 years of age. The 
incidence of NIDDM increase with age and increasing obesity.  
• Other types of diabetes mellitus include: malnutrition-related diabetes 
mellitus (MRDM), gestational diabetes mellitus (GDM), and impaired 
glucose tolerance (IGT) (Roger, et al, 1999). 
Clinical manifestations:  
The symptoms are similar in IDDM and NIDDM but may vary in 
their intensity. Common symptoms include polyuria and polydipsia, 
which are consequences of osmotic diuresis secondary to sustained 
hyperglycaemia. In NIDM if the diagnosis is not made early, common 
feature of hyperglycaemia when present will lead to diabetic ketoacidosis. 
Lowered plasma volume produce dizziness and weakness due to postural 
hypotension. Ketoacidosis exacerbate the dehydration and 
hyperosmolality by producing anorexia, nausea and vomiting.  
In NIDDM have an insidious onset of hyperglycaemia and they 
may have more of classical symptoms. Chronic skin infections are 
common as sustained hyperglycaemia can result in severe impairment of 
phagocyte function. Prolonged exposure to hyperglycaemia by the patient 
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in NIDDM results in retinopathy and peripheral vascular disease (Roger, 
et al, 1999).  
Treatment:  
The aim of the treatment is to alleviate the symptoms of thirst, 
polyuria, polydipsia, weight loss and ketoacidosis. 
 Persistent hyperglycaemia is the major controllable factors that 
influence the development of diabetic complications.  
In IDDM the treatment rely on the administration of exogenous 
insulin. There are different types of insulin preparations used. These 
insulin types are: neutral human insulin, biphasic insulin, insulin zinc 
suspension (mixed), and insulin zinc suspension (crystalline).  
The drugs used in the treatment of NIDDM mellitus are: 
sulphonylureas and biguanides. The sulphonylureas are classified into: 
first generation and second generation. Example of first generation 
sulphonyureas are; tolbutamide, chloropropamide and tolazamide. The 
members of second generation sulphonylureas one; glibencalamide, 
glipizide and gliclazide.  The biguanides family include; metformin 
(Roger, et al, 1999).             
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OBJECTIVES 
 
• To study pharmacodynamic drug interaction between β-blockers and 
some chemotherapeutic agents. 
• To investigate the mentioned interactions among patients with 
chronic tropical diseases. 
• To select a suitable drug regimen for suitable case by minimizing 
pharmacoeconomic aspect. 
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CHAPTER TWO 
 MATERIALS AND METHODS 
 
2.1. Materials    
        2.1.1 Chemicals & Drugs: 
Source Chemical substance No. 
Merck  Sodium chloride  1. 
Merck - India Sodium bicarbonate 2. 
Seelze Hanover - Germany Calcium chloride  3. 
Seelze Hanover - Germany Potassium chloride  4. 
BDH chemical Poole - England Magnesium chloride 5. 
Seelze Hanover - Germany Sodium dihydrogen ortho-phosphate 6. 
BDH chemical Poole - England D – Glucose 7. 
BDH chemical Poole - England Potassium dihydrogen phosphate 8 
Fisher – U. S. A Magnesium sulphate 9 
Lohman & Rausher Laboratory Adrenaline  amp. 10 
Amipharma laboratories-Sudan Propranalol Hydrochloride  11 
Sigma – U . S . A Tolazoline  12 
Amipharma laboratories-Sudan Atenolol  13 
Shing poong - Korea INH 14 
France Chloroquine phosphate amp. 15 
Vogram-Germmany Quinine dihydrochloride 16 
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2.1.2 Equipment:  
Source Name of the apparatus Ser. No. 
Harvard apparatus ltd., U.S.A. Harvard organ bath 1. 
Harvard apparatus ltd., U.S.A. Harvard universal oscillograph 2. 
England. Pump 3. 
Japan. Electrical sensitive balance 4. 
France. Oxygen cylinder 5 
 
2.1.3  Laboratory Animals:  
I . Rabbits :  Healthy ( Local strain ), weighing 1 -3 kg . 
II . Frogs: obtained from the Faculty of Science, University of  Khartoum.     
III. Albino Rats. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 32
2.2. METHODS:  
2.2.1. Isolated rabbit aortic strip:     
 The preparation was based on the method of Furchgott and 
Bhadrakom (1953). The Rabbit was killed by a blow on the neck and the 
animal was exsanguinated. The chest was opened, the internal viscera 
was pulled to one side exposing the aorta. The aorta was cut close to the 
heart as far as possible and transferred to a Petri dish containing aerated 
Krebs ringer solution and divided into pieces of 3 – 4cm length. One of 
these pieces was located over the large serum needle to facilitate 
preparation of the tissue. All surrounding fats and connective tissue were 
removed, and then the aorta was cut spirally using curved scissor so as to 
produce a continuous strip. 
Thread was tied to each end of the strip; one end was attached to 
the tissue holder. Then the mounted tissue was transferred to an organ 
bath and the upper thread was attached to a transducer and left for 45 
minutes to equilibrate. Then the drug was added to determine the effects, 
also different antagonists were used to block the effect (Ian Kitchen, 
1980). 
2.2.2. In situ frog heart:     
              Frog weighed 150-200 gm was pithed (damage the spinal cord by 
using pithing needle). The abdomen and the thorax were opened and the 
heart was exposed, the pericardium membrane was carefully removed.  
The apex of the heart was connected to recording system by heart clip. 
Then tested drugs were added to the in situ heart by drop wise and the 
response was recorded (Lab Practical sheet). 
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2.2.3. Isolated rat vas deferens preparation:     
An albino rat weighing 120 – 140 gm was killed by a blow on the 
head and cutting the throat. The abdomen was opened by making 
longitudinal cut from penis up to the rib cage. The gut was lifted to one 
side and the terminal end of the colon was raised to expose the 
hypogastric nerves, which run on either side of the mesentery attached to 
the colon. The preparation was kept moisten with Ringer solution. The 
vas deferens is easily identified as it is white in color and runs from the 
epididymis close to the testis to where it joints to the urethra. The testis 
were pushed forward into the abdomen by applying pressure to the 
scrotum. Both vasa are free to dissect. One vas was cut just above the 
epididymis and carefully dissect the muscle towards the urethra. The vasa 
was freed by cutting at the urethra taking care to leave the nerve supply 
intact. The free vas deferens was transferred to a Petri dish containing 
Ringer solution (Kreb’s) and aerated with oxygen gas. One end of the vas 
was tied to the holder of the organ bath and the end was connected to an 
isometric transducer (Ian Kitchen, 1984).   
2.3. Experimental Design:  (in situ frog heart)  
For the in situ frog heart experiment tissue, a non smoked 
kymograph drum was used. 
- Drum speed was 1.2 mm sec. 
- Added drugs were prepared in volumetric solutions. 
2.3.1. Drugs addition sequence:- 
A-1 
The normal heart rhythm was recorded for 15 seconds. 
- A dose of 1ug isoniazid (INH) was added to the frog heart, and the 
heart response was recorded for 15 seconds. 
- The heart was washed with clark frog physiological solution. 
- A period of 2 minutes was elapsed. 
 34
- The normal heart rhythm was traced for 30 seconds. 
A-2  
- A dose of 2ug INH was added to the heart. 
- The heart response was recorded. 
- The heart was washed with Clark-frog solution. 
- The normal heart rhythm was traced for 30 seconds. 
B:- 
- The dose of 5ug propranolol (or atenolol) was added to the frog 
heart. 
- The heart was washed with Clark-soluation. 
- A period of 2min resting was elapsed. 
- The normal heart rhythm was recorded for 30 seconds. 
C:- 
The combinations of two doses of 1ug INH + 5ug propanolol were 
added concurrently to the heart. 
- The heart rhythm was recorded. 
D:-  
The effects of Quinine and atenolol on in situ frog heart. 
- Kymograph drum speed was adjusted at the speed of 1.2 mm 
second. 
- The normal heart rhythm was recorded in duration of 15 seconds. 
- A dose of 1ug/ml Quinine (Qne) was added to the frog heart and 
the heart rhythm was traced for 30 seconds. 
- The heart was been washed with frog heart solution. 
- The normal heart rhythm was recorded. 
- A dose of 2ug/ml QNE was added to the heart and the rhythm was 
recorded. 
- The heart was washed with Clark’s solution. 
- A rest period of 30 seconds was elapsed. 
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- The heart rhythm was recorded for 15 seconds. 
- A dose of 5ug atenolol (Atn) was added to the heart and the heart 
beats were traced. 
- The heart was washed with Clark’s solution and a rest period of 15 
seconds was elapsed. 
- The combination doses of 1ug/ml QNE + 5ug/ml atenolol were 
added concurrently to the heart.  The heart rhythm was recorded. 
 
Note: - The same experiment was carried out using two different doses of 
isoniazed (INH), 1ug and 2ug/ml    respectively in additions to a dose of 5ug/ml 
atenolol (Time interval between doses is 15 seconds). 
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2.4. Experimental Design of rabbit aortic strip:   
A reservoir capacity of 1.5 litre (approx) is connected to the 
organ gut bath via an infusion tube. An injection port located midway 
between the reservoir and the organ gut bath. The injection port is used 
for the intermittent injections of INH, Que, and chloroquine (CQ) 
different doses. In all experiments the chart baseline of Krebs solution 
response was recorded for 10 minutes.  
 
Experiment A:   
•  The reservoir contained 1 µg/ml adrenaline in Krebs physiological 
solution.  
• The interval between different doses is 5 minutes.  
• The reservoir containing 1 µg/ml adrenaline in Krebs was infused to 
organ gut both containing the rabbit aortic strip via a peristaltic pump.  
• The reservoir solution was infused to the organ gut-bath for 15 minute, 
and the response was recorded.  
• An injection of 100 µ/ml INH was injected at the port site and the 
response was traced.  
• The organ-bath was drained off.  
•  An injection of 200 µg/ml INH was injected after 5 minutes from the 
previous dose and the response was traced.  
• The solution in the organ bath was drained off.  
• The solution contained in the reservoir was infused just to fill the organ 
bath.  
• An injection of 400 µg/ml chloroquine was injected and the response 
was recorded.  
• The organ bath solution was replaced by the reservoir contents.  
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• An injection of 800 µg/ml chloroquine was injected and the response 
was traced.  
• The organ bath contents was drained off and replaced by fresh 
physiological solution.  
• An injection of 100 µg/ml quinine was injected and the response was 
recorded.  
•  After 5 minutes the organ bath content was removed and been replaced 
by fresh Krebs’s solution.  
• An injection of 200 µg/ml quinine was added and the response was 
traced.  
 
Experiment B:   
•  The reservoir contained 1 µg/ml adrenaline + 10 µg/ml atenolol in 
Krebs’s solution.  
• The interval between different doses is 5 minutes.  
• The reservoir content was infused to organ bath for 15 minutes and 
response was recorded. 
• An injection of 100 µ/ml INH was added and the response was 
recorded.  
• The organ-bath contents were drained off and replaced by fresh Krebs’s 
solution.  
•  An injection of 200 µg/ml INH was injected into the part site and the 
response was traced.   
• The organ bath solution was removed and replaced by fresh Krebs’s 
solution.  
•  An injection of 400 µg/ml chloroquine was added to the organ bath via 
the infusion tube, and the response was recorded.  
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• The organ bath content was removed and replaced by fresh Krebs’s 
solution.  
• An injection of 800 µg/ml chloroquine was injected to the organ bath, 
and the response was recorded.  
• The organ bath’s contents was removed and replaced by fresh Krebs’s 
solution.  
• An injection of 100 µg/ml quinine was injected and the response was 
traced.   
• The organ bath content was drained off and replaced by fresh Krebs’s 
solution.  
• An injection of 200 µg/ml quinine was injected at the port site and the 
response was recorded.  
 
Experiment C:   
•  The reservoir contained 10 µg/ml Tolazoline + 1 µg/ml adrenaline in 
Krebs solution.  
• The solution of the reservoir was infused to the organ bath and the 
response was traced for a period of 15 minutes.  
• An injection of 100 µ/ml INH was added and the response was 
recorded.  
•  An injection of 200 µg/ml INH was added after drainage of organ bath 
content and the response was recorded.     
• The organ bath was drained off and replaced by fresh Krebs’s solution.  
• An injection of 400 µg/ml chloroquine was injected at port site and the 
response was traced.  
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Krebs physiological solution composition:- 
 Krebs Quantities per litre 
Nacl 6.9g 
Kcl 10% 305ml 
MgSo4 6H2O 10% 2.9ml 
KH2 PO4 10% 1.6ml 
Glucose 2   gm 
NaHCo3 2.1gm 
Cacl2 2.52ml 
Areating gas O2 + 5% Co2 
 
(Pharmacological Experiments on isolated preparations, p.2 1970) 
 
Clark-frog ringer physiological solution, Quantities of salt are (per litre) 
 Krebs Quantities per litre 
Nacl 6.5gm 
Kcl 0.14gm 
Cacl 0.12gm 
NaH2P2o 0.01gm 
Na Hco3 0.2gm 
Glucose 2    gm 
 
(Pharmacological Experiments on isolated preparations, p.2 1970) 
 
2.5. Statistical method:  
Statistical method use is one-sample student t-test. 
 
 
 40
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 41
Table (3 -1):- Shows the effect of INH and atenolol on the in situ 
frog heart. The addition of INH alone or with atenolol to frog heart 
produced no significant effect on   the heart peaks (P≥0.05). 
 
 Using 1µg INH the mean number of peaks obtained was                
12.83 ± 0.75 of the mean amplitude mm obtained was 5.5. 
 
 Using 2µg INH the mean number of peaks obtained was                 
12.17 ± 0.92 where as the mean amplitude was 5.33  ± 0.7. 
 
Using 5µg atenolol the mean number of peaks obtained was 12.17 ± 1.0 
where as the mean amplitude obtained was 5.6  ± 0.75. 
 
 Using 1µg INH and 5mg ATN the mean number of peaks obtained 
was 11.67 ± 1.2 and the mean amplitude obtained was 5.33  ± 0.9. 
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Table (3-2):- Shows the effect of INH and propranolol on the in situ frog 
heart. The addition of INH alone or propranolol to frog heart showed no 
significant effect, but concurrent addition of both INH + propranolol 
produced significant decrease in the number of heart peaks (P≥0.05).  
Using INH alone the mean was 17 ± 0.9 where the amplitude was             
4.17 ± 0.6.  
 
 The addition of INH in a dose of 2µg result in a reduction of the 
numbers of peaks mean 15.83  ± 0.54 and amplitude mean was 3.34± 0.8.  
 
Using propronolol in a dose of 5µg the numbers of peaks mean was 
17.5 ±  2.6 and the amplitude mean was 3.11  ± 0.9. 
 
But the concurrent addition of 1µg INH with 5µg propranolol 
result in significant reduction of peaks numbers 14.33  ± 0.9 and 
amplitude mean was 2.72  ± 0.9. 
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Table (3-3):- Shows the effect of Quinine 2Hcl and atenolol on the 
in situ frog heart.  The addition of Quinine alone or with atenolol to frog 
heart produced no significant effect on the heart peaks. 
 
Using 1µg Quinine the means peaks number obtained was 15± 0.93 
and the mean of amplitude was 14.15  ± 0.54. 
 
Using 2µg Quinine obtained peak number of 15.33  ±  1.0 and the 
amplitude mean was 4.5  ± 0.56. 
 
Using a dose of 5µg Quinine and 5µg atenolol resulted with mean 
number of peaks of 14.5  ±  0.75 and amplitude mean was 4.42 ± 0.5. 
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Table 4 
Experiment (1) 
Effect of chemotherapeutic agents on the response of the rabbit 
aortic strip to Adrenaline 
 
 
Treatment Change /cm % change 
 Control Value  
Adr + INH (100 µg) 0.1 ml B.L  (13.00) 13.9 + 6.0 
Adr + INH (200 µg) 0.2 ml  13.9 + 6.0 
Adr + CQ (400 µg) 0.1 ml B.L (11.8)  11.9 + 0.84 
Adr +  CQ (800 µg) 0.2 ml  12.9 +1.6 
Adr + QNE (100 µg)  0.05 ml B.L ( 11.7)  11.7 00.00 
Adr + QNE (200 µg) 0.1 ml  11.7 00.00 
 Control Value  
Adr + ATN+ INH (100 µg) 0.1 ml B.L (11.8) 11.85 + 0.42 
Adr + ATN+ INH (200 µg g) 0.2 ml  11.9 + 0.84 
Adr + ATN+ CQ (400 µg) 0.1 ml B.L (10.8)  10.7 - 0.92 
Adr + ATN+ CQ (800 µg) 0.2 ml  10.4 - 3.71 
Adr + ATN+ QNE (100 µg) 0.05ml B.L (11.4) 11.2 - 1.7 
Adr + ATN+ QNE (200 µg) 0.1 ml  11.15 - 2.6 
 Control Value  
Adr + Tolz + INH (100 µg) 0.1 ml B.L ( 8.8)  8.8  00.00 
Adr + Tolz + INH (200 µg) 0.2 ml   8.8  00.00 
Adr + Tolz + CQ (400 µg) 0.1 ml B.L ( 8.7)  7.00 -19.5 
Adr + Tolz + CQ (800 µg) 0.1 ml   5.6 -35.6 
Adr + Tolz + QNE (100 µg) 0.05 ml B.L ( 8.00)  7.25 - 9.37 
Adr + Tolz + QNE (200 µg) 0.1 ml   7.1 -11.25 
 
Pre treatment level (B.L. = Base line) 
 
 Drug response – B.L. (cm)   
% change = _______________________ X 100 = _______ 
 B.L. (cm)   
 
? Adr   = Adrenaline 
? INH   = Isoniazid. 
? CQ     = Chloroquine 
? QNE  = Quinine. 
? ATN  = Atenolol 
? Tolz  = Tolazoline 
 
Washing with Krebs between two different doses (15min). 
Time interval between doses = 5 min.  
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Table 4:- Shows the effect of chemotherapeutic agents on the 
response of rabbit aortic strip to adrenaline.  
  
A 6.9% change was obtained by administering Adr (0.5µg) + INH 
(100µg) 0.1ml. 6.9 changes were obtained by administering Adr + INH 
(200µg) 0.2ml.  0.84% change was obtained after using Adr (0.5µg) + 
CQ (400µg) 0.1 ml, 1.6% change was obtained after using Adr(0.5µg) + 
CQ (800µg) 0.2 ml.  No change was seen after using Adr(0.5µg) + QNE 
(100µg) 0.05 ml. 
 
 A 0.42% change was obtained using Adr(0.5µg) + 10µg atenolol + 
INH (100µg).  0.84% change was obtained after using Adr(0.5µg) + 10µg 
atenolol + 200µg INH.  9.2% change was obtained after using 
Adr(0.5µg)+ 10µg atenolol + 400µg chloroquine (CQ) where as a – 
3.71% change obtained using Adr(0.5µg) + 10µg atenolol + 800µg 
chloroquine (CQ). 
 
 A -1.7% change was obtained using 0.5µg Adr + 10µg Quinine 
(QNE).  A -2.6% was obtained using 0.5µg Adr + 10µg atenolol + 200µg 
QNE. 
  
The addition of 0.5µg Adr + 10µg Tolazoline + 100µg INH and the 
addition of 0.5µg Adr + 10µg Tolazoline + 200µg INH insult in 00.00%, 
which is not significant change.  
  
 
A -19.5% change was obtained sing 0.5µg Adr + 10µg Tolazoline 
+ 400µg  CQ.   A -35.6% change was obtained using 0.5µg Adr + 10µg 
Tolz + 800µg CQ while the addition of 0.5µg Adr + 10µg Tolz + 100µg 
QNE resulted in -9.37% changes.  A -11.25% change was obtained using 
0.5µg Adr + 10µg Tolz +200µg QNE. 
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Table 5 
 
Experiment (2) 
Effect of chemotherapeutic agent on the response of the rabbit  
aortic strip to Adrenaline 
 
Treatment Change /cm % change 
 Control Value  
Adr + INH (100 µg) 0.1 ml B.L  ( 5.5) 5.9 +  7.2 
Adr + INH (200 µg) 0.2 ml   6.1 +10.9 
Adr + CQ (400 µg) 0.1 ml B.L  ( 7.8)   8.75 +12.1 
Adr +  CQ (800 µg) 0.2 ml   9.3 +19.2 
Adr + QNE (100 µg)  0.05 ml B.L ( 9.00)   9.35 + 3.88 
Adr + QNE (200 µg) 0.1 ml   9.30 + 3.88 
 Control Value  
Adr + ATN+ INH (100 µg) 0.1 ml B.L ( 9.00)  9.6 + 6.66 
Adr + ATN+ INH (200 µg) 0.2 ml   9.6 + 6.66 
Adr + ATN+ CQ (400 µg) 0.1 ml B.L ( 8.1)   8.00 - 1.23 
Adr + ATN+ CQ (800 µg) 0.2 ml   7.95 - 1.85 
Adr + ATN+ QNE (100 µg) 0.05ml B.L ( 7.7) 7.7  00.00 
Adr + ATN+ QNE (200 µg) 0.1 ml  7.5 - 2.59 
 Control Value  
Adr + Tolz + INH (100 µg) 0.1 ml B.L ( 7.5) 7.5 00.00 
Adr + Tolz + INH (200 µg) 0.2 ml  7.4 -1.3 
Adr + Tolz + CQ (400 µg) 0.1 ml B.L ( 5.9) 5.35 - 9.32 
Adr + Tolz + CQ (800 µg) 0.1 ml  5.1 -13.55 
Adr + Tolz + QNE (100 µg) 0.05 ml B.L ( 5.6) 5.6  00.00 
Adr + Tolz + QNE (200 µg) 0.1 ml  5.7 + 1.8 
 
Pre treatment level (B.L. = Base line) 
 
 Drug response – B.L. (cm)   
% change = _______________________ X 100 = _______ 
 B.L. (cm)   
 
? Adr   = Adrenaline 
? INH   = Isoniazid. 
? CQ     = Chloroquine 
? QNE  = Quinine. 
? ATN  = Atenolol 
? Tolz  = Tolazoline 
 
Washing with Krebs between two different doses (15min). 
Time interval between doses = 5 min.  
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Table 5:- Shows the effect of chemotherapeutic agents on the response of 
the rabbit aortic strip to adrenaline.  A 7.2% changes were obtained using 
0.5µg Adr +100µg INH (0.1ml).  A 10.9% change was produced using 
0.5µg Adr + 200µg INH.  A 12.1% change was obtained using a 0.5µg 
Adr + 400µg CQ, while a 19.2% change were produced using 0.5µg Adr 
+ 800µg CQ. 
 
 A 3.88% change was obtained using 0.5µg Adr + 100µg QNE.  A 
3.88% change was obtained using 0.5µg Adr + 200µg QNE. 
 
 A 6.66% change was obtained using 0.5µg Adr + 10µg atenolol + 
100µg INH.  A6.66% change was obtained using 0.5µg Adr + 10µg 
atenolol + 200µg INH. 
 
 A -1.23% change was produced using 0.5µg Adr +10µg atenolol 
+400µg CQ.   A -1.85% change as a result of the addition of 0.5µg Adr 
+10µg atenolol + 800µg CQ. 
 
 A 00.00% change was obtained using 0.5µg Adr + 10µg atenolol + 
200ug QNE.  A 00.00% change was obtained when a 0.5µg Adr + 10µg 
Tolz + 100µg INH were added. 
 
 A -1.3% change s a result of the addition of 0.5µg Adr + 10µg Tolz 
+ 200µg INH.A -9.32% changes were obtained using 0.5µg Adr + 10µg 
Tolz + 400µg CQ.  A -13.55% change was produced upon the addition of 
0.5µg Adr + 10µg Tolz + 800µg CQ. 
 
A 00.00% change was obtained using 0.5µg dr + 10µg Tolz + 
100µg QNE.  Where a 1.8% change as a result of the addition of 0.5µg + 
10µg Tolz + 200µg QNE. 
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Table 6 
 
Experiment (3) 
 
Effect of chemotherapeutic agent on the response of the rabbit Aortic 
strip to Adrenaline 
 
 
Treatment Change /cm % change 
 Control Value  
Adr + INH (100 µg) 0.1 ml B.L  ( 11.5) 12.5 + 8.69 
Adr + INH (200 µg) 0.2 ml  12.55 + 9.13 
Adr + CQ (400 µg) 0.1 ml B.L  ( 6.1)   6.25 + 2.45 
Adr +  CQ (800 µg) 0.2 ml   6.2 + 1.63 
Adr + QNE (100 µg)  0.05 ml B.L  ( 6.45)   6.6 + 4.7 
Adr + QNE (200 µg) 0.1 ml   6.7 + 6.3 
 Control Value  
Adr + ATN+ INH (100 µg) 0.1 ml B.L ( 7.5)  8.25 +10.00 
Adr + ATN+ INH (200 µg) 0.2 ml   8.3 +10.6 
Adr + ATN+ CQ (400 µg) 0.1 ml B.L ( 8.5)   8.4 - 1.17 
Adr + ATN+ CQ (800 µg) 0.2 ml   8.45 - 0.58 
Adr + ATN+ QNE (100 µg) 0.05ml B.L ( 9.2)  9.2  00.00 
Adr + ATN+ QNE (200 µg) 0.1 ml   9.2  00.00 
 Control Value  
Adr + Tolz + INH (100 µg) 0.1 ml B.L ( 7.00)  7.1 + 1.4 
Adr + Tolz + INH (200 µg) 0.2 ml  7.00  00.00 
Adr + Tolz + CQ (400 µg) 0.1 ml B.L ( 6.7)  6.6 - 1.49 
Adr + Tolz + CQ (800 µg) 0.1 ml   6.5 - 2.98 
Adr + Tolz + QNE (100 µg) 0.05 ml B.L ( 7.4)  7.4  00.00 
Adr + Tolz + QNE (200 µg) 0.1 ml   7.5 + 1.4 
 
Pre treatment level (B.L. = Base line) 
 
 Drug response – B.L. (cm)   
% change = _______________________ X 100 = _______ 
 B.L. (cm)   
 
? Adr   = Adrenaline 
? INH   = Isoniazid. 
? CQ     = Chloroquine 
? QNE  = Quinine. 
? ATN  = Atenolol 
? Tolz  = Tolazoline 
 
 
Washing with Krebs between two different doses (15min). 
Time interval between doses = 5 min.  
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Table 6:- Shows the effect of chemotherapeutic agents on the response of 
the rabbit aortic strip to adrenaline A 8.69% change was obtained using 
0.5µg Adr + 100µg INH.  Where a 9.13% changes were produced upon 
the addition of 0.5µg Adr + 200µg INH. 
 
 A 2.45% change was obtained using 0.5µg Adr + 400µg CQ.  
While a 1.63% change was a result of the addition of 0.5µg Adr +  800µg 
CQ. 
 
A -1.6% change was obtained using 0.5µg Adr +100µg QNE.  A 
6.3% change was obtained using 0.5µg Adr + 200µg QNE. 
 
A10.00% change was obtained using 0.5µg Adr + 10µg Atenolol + 
100µg INH.  A 10.6% change was a result of addition of 0.5µg Adr + 
10µg atenolol + 200µg INH. 
 
A -1.17% changes were obtained using 0.5µg Adr +10µg atenolol 
+ 400µg CQ.  A -0.58 was obtained using 0.5µg Adr + 10µg atenolol + 
800µg CQ. 
 
A 00.00% changes was obtained using a 0.5µg Adr + 10µg 
atenolol +200µg QNE resulted in 00.00% change. 
 
A 1.4% change was obtained using 0.5µg Adr + 10µg Tolz + 
100µg INH.  A 00.00% change was obtained using 0.5µg Adr +10µg 
Tolz + 200µg INH.  A -1.48% change was obtained using 0.5 µg Adr + 
10µg Tolz + 400µg CQ.  
 
A -2.98% Change was obtained using 0.5µg Adr + 10µg Tolz + 
800µg CQ. 
 
A 00.00% change was produced using 0.5µg Adr + 10µg Tolz + 
100µg QNE.  A +1.4% change was obtained using 0.5µg Adr + 10µg 
Tolz  + 200µg QNE. 
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Table 7 
 
Experiment (4) 
Effect of chemotherapeutic agents on the response of the rabbit 
Aortic strip to Adrenaline 
 
 
Treatment Change /cm % change 
 Control Value  
Adr + INH (100 µg) 0.1 ml B.L  ( 9.9)   9.5 + 5.5 
Adr + INH (200 µg) 0.2 ml    9.7 + 7.7 
Adr + CQ (400 µg) 0.1 ml B.L  (10.1)  11.00 + 8.9 
Adr +  CQ (800 µg) 0.2 ml  10.9 + 7.9 
Adr + QNE (100 µg)  0.05 ml B.L  (11.1) 11.2 + 0.900 
Adr + QNE (200 µg) 0.1 ml  11.4 + 2.70 
 Control Value  
Adr + ATN+ INH (100 µg) 0.1 ml B.L (12.85) 13.45 + 4.66 
Adr + ATN+ INH (200 µg) 0.2 ml  13.45 + 4.66 
Adr + ATN+ CQ (400 µg) 0.1 ml B.L (11.4)  11.35 - 4.0 
Adr + ATN+ CQ (800 µg) 0.2 ml  10.95 - 4.3 
Adr + ATN+ QNE (100 µg) 0.05ml B.L (11.95) 12.00 + 0.4 
Adr + ATN+ QNE (200 µg) 0.1 ml  12.00 + 0.4 
 Control Value  
Adr + Tolz + INH (100 µg) 0.1 ml B.L (  8.55)  8.6 + 0.58 
Adr + Tolz + INH (200 µg) 0.2 ml   8.6 + 0.58 
Adr + Tolz + CQ (400 µg) 0.1 ml B.L (  7.15)  7.05 - 1.39 
Adr + Tolz + CQ (800 µg) 0.1 ml   6.55 - 8.39 
Adr + Tolz + QNE (100 µg) 0.05 ml B.L (  8.6)  6.7 - 1.47 
Adr + Tolz + QNE (200 µg) 0.1 ml   6.7 - 1.47 
 
Pre treatment level (B.L. = Base line) 
 
 Drug response – B.L. (cm)   
% change = _______________________ X 100 = _______ 
 B.L. (cm)   
 
? Adr   = Adrenaline 
? INH   = Isoniazid. 
? CQ     = Chloroquine 
? QNE  = Quinine. 
? ATN  = Atenolol 
? Tolz  = Tolazoline 
 
Washing with Krebs between two different doses (15min) . 
Time interval between doses = 5 min.  
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Table (7):- Shows the effect of chemotherapeutic agents on the response 
of the rabbit Aortic strip to Adrenaline. A 5.5% change was obtained 
using 0.5µg Adr + 100µg INH.  Where as 7.7% change was produced 
using 0.5µg Adr + 200µg INH.  
 
 A8.8% changes obtained using 0.5µg Adr + 400µg Chloroquine 
CQ.  The addition of 0.5µg INH + 800µg CQ result in 7.9% changes. 
 
 A 0.900% change was obtained using 0.5µg Adr + 100µg QNE.  A 
2.7% changes were obtained upon the addition of 0.5µg Adr + 200µg 
QNE. 
 
 A 4.66% changes were obtained using 0.5µg Adr + 10µg atenolol 
+ 400µg INH.  Where as a 4.66% changes were the result of the addition 
of 0.5µg atenolol + 400µg chloroquine CQ.   
 
A -4.3% was obtained using 0.5µg Adr + 10µg atenolol + 800µg 
chloroquine CQ.  A 0.4 % change result upon the addition of 0.5µg Adr + 
10µg atenolol + 100µg QNE. 
 
The addition of a 0.5µg Adr + 10µg Tolz + 100µg INH result in a 
percent change of 0.58%.  Where as the addition of 0.5µg Adr + 10µg 
Tolz + 200µg INH result in a percent change of 0.58%. 
 
A -1.39% change was obtained using 0.5µg Adr + 10µg Tolz + 
400µg chloroquine. 
 
A -8.39% change was obtained using 0.5µg Adr + 10µg Tolz + 
800µg CQ.  A -1.47% change was obtained using 0.5µg Adr + 10µg Tolz 
+ 100µg QNE.  A -1.47% change was the result of the addition of 0.5µg 
Adr + 10µg Tolz + 200µg QNE.  
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Table 8 
 
Experiment (5) 
 
Effect of chemotherapeutic agents  on the response of the rabbit 
Aortic strip to Adrenaline 
 
 
Treatment Change /cm % change 
 Control Value  
Adr + INH (100 µg) 0.1 ml B.L  ( 5.5)  6.0 + 9.00 
Adr + INH (200 µg) 0.2 ml   6.2 +12.7 
Adr + CQ (400 µg) 0.1 ml B.L  ( 7.2)   7.5 + 4.1 
Adr + CQ (800 µg) 0.2 ml   7.3 + 1.3 
Adr + QNE (100 µg)  0.05 ml B.L  ( 8.9)   9.7 + 8.98 
Adr + QNE (200 µg) 0.1 ml   9.4 +11.23 
 Control Value  
Adr + ATN+ INH (100 µg) 0.1 ml B.L ( 6.9 )  6.9  00.00 
Adr + ATN+ INH (200 µg) 0.2 ml   6.9  00.00 
Adr + ATN+ CQ (400 µg g) 0.1 ml B.L  ( 6.3)   6.15 - 2.38 
Adr + ATN+ CQ (800 µg) 0.2 ml   6.4 +1.58 
Adr + ATN+ QNE (100 µg) 0.05ml B.L ( 4.75)  4.55 - 4.2 
Adr + ATN+ QNE (200 µg) 0.1 ml   4.1 -13.6 
 Control Value  
Adr + Tolz + INH (100 µg) 0.1 ml B.L ( 3.5) 3.5 00.00 
Adr + Tolz + INH (200 µg) 0.2 ml   3.5 00.00 
Adr + Tolz + CQ (400 µg) 0.1 ml B.L ( 1.9)  1.7 -10.5 
Adr + Tolz + CQ (800 µg) 0.1 ml   1.5 -21.00 
Adr + Tolz + QNE (100 µg) 0.05 ml B.L ( 2.00)  1.8 -10.00 
Adr + Tolz + QNE (200 µg) 0.1 ml   1.7 -15.00 
 
Pre treatment level (B.L. = Base line) 
 
 Drug response – B.L. (cm)   
% change = _______________________ X 100 = _______ 
 B.L. (cm)   
 
? Adr   = Adrenaline 
? INH   = Isoniazid. 
? CQ    = Chloroquine 
? QNE  = Quinine. 
? ATN  = Atenolol 
? Tolz  = Tolazoline 
 
Washing with Krebs between two different doses (15min). 
Time interval between doses = 5 min.  
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Table (8):- Shows effect of chemotherapeutic agents on the response of 
the rabbit Aortic strip to Adrenaline.  A 9.00% change was obtained using 
0.5µg Adr + 100µg INH.  A 12.7% changes were produced using 0.5µg 
Adr + 200µg  INH 
 
 A 4.1% change was obtained using 0.5µg Adr + 400µg 
Choloroquine CQ.  Where as 1.3% change was produced as a result of the 
addition of 0.5µg Adr + 800µg chloroqine CQ. 
 
 The addition of 0.5µg Adr + 100µg QNE + result in a percent 
change of 8.98.  A 11.23% changes were obtained using 0.5µg  Adr + 
200µg  QNE. 
 
 A 00.00% change was obtained using 0.5µg Adr + 10µg  atenolol 
+ 100µg  INH.  Where as 00.00% change was produced upon the addition 
of 0.5µg  Adr + 10µg  atenolol + 200µg  INH. 
 
 
 A -2.38% change was obtained using 0.5µg atenolol + 400µg CQ.  
A 1.58% change was obtained using 0.5µg  Adr + 10µg  atenolol + 
800µg  CQ. 
 
 A -4.2% change was the result of the addition of 0.5µg  Adr + 
10µg  atenolol +100µg  QNE.  A -13.6% change was obtained using 
0,5µg Adr + 10µg atenolol + 200µg QNE. 
 
 A 00.00% change was obtained using 0.5µg Adr + 10µg Tolz + 
100µg INH.  Where as the addition of 0.5µg Adr + 10µg Tolz + 200µg 
INH result in a % change of 00.00%.  
 
 A -10.5% Change was obtained using 0.5µg Adr + 10µg Tolz + 
400µg CQ.  Where as the addition of 0.5µg Adr + 10µg Tolz + 800µg 
CQ result in a % change of -21.00. 
 
A 10.00% change was obtained using 0.5µg Adr + 10µg 
Tolz + 100µg QNE.  Where as The addition of 0.5µg Adr + 10µg 
Tolz + 200µg QNE result in a percent (%) change of -15.00.   
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Table 9 
 
Experiment (6) 
Effect of chemotherapeutic agents on the response of the rabbit 
Aortic strip to Adrenaline 
 
 
Treatment Change /cm % change 
 Control Value  
Adr + INH (100 µg) 0.1 ml B.L  ( 6.7)  7.4 +10.4 
Adr + INH (200 µg) 0.2 ml   7.6 +13.4 
Adr + CQ (400 µg) 0.1 ml B.L  ( 6.7)   7.2 +  7.4 
Adr +  CQ (800 µg) 0.2 ml   7.1 +  5.9 
Adr + QNE (100 µg)  0.05 ml B.L (  8.6)   8.7 +  1.16 
Adr + QNE (200 µg) 0.1 ml   8.8 +  2.3 
 Control Value  
Adr + ATN+ INH (100 µg) 0.1 ml B.L ( 9.8) 11.6 +18.36 
Adr + ATN+ INH (200 µg) 0.2 ml  11.5 +17.34 
Adr + ATN+ CQ (400 µg) 0.1 ml B.L ( 9.5)   9.3 -   2.10 
Adr + ATN+ CQ (800 µg) 0.2 ml   9.00 -   5.26 
Adr + ATN+ QNE (100 µg) 0.05ml B.L ( 9.1)  9.2 +  1.1 
Adr + ATN+ QNE (200 µg) 0.1 ml   9.3 +  2.2 
 Control Value  
Adr + Tolz + INH (100 µg) 0.1 ml B.L ( 5.3)  5.2 -  1.88 
Adr + Tolz + INH (200 µg) 0.2 ml   5.2 -  1.88 
Adr + Tolz + CQ (400 µg) 0.1 ml B.L ( 6.9)  6.7 -  2.8 
Adr + Tolz + CQ (800 µg) 0.1 ml   6.6 -  4.3 
Adr + Tolz + QNE (100 µg) 0.05 ml B.L ( 1.9)  1.8 -  5.3 
Adr + Tolz + QNE (200 µg) 0.1 ml   1.7 -10.5 
 
Pre treatment level (B.L. = Base line) 
 
 Drug response – B.L. (cm)   
% change = _______________________ X 100 = _______ 
 B.L. (cm)   
 
? Adr   = Adrenaline 
? INH   = Isoniazid. 
? CQ    = Chloroquine 
? QNE  = Quinine. 
? ATN  = Atenolol 
? Tolz  = Tolazoline 
 
 
Washing with Krebs between two different doses (15min). 
Time interval between doses = 5 min.  
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Table (9):- Shows the effect of chemotherapeutic agents on the response 
of the rabbit Aortic strip to Adrenaline.  A 10.4% change was obtained 
using 0.5µg Adr + 100µg INH.  A 13.4% change was obtained using 
0.5µg Adr + 200µg INH. 
 
 A 7.4% was obtained using 0.5µg Adr + 400µg CQ.  Where as the 
addition of 0.5µg Adr + 800µg CQ result in percent change of 5.9. 
 
 A 1.16% change was obtained using 0.5µg Adr + 100µg QNE.  
The addition of 0.5µg Adr + 200µg QNE result in percent change of 2.3. 
 
 A 18.36% changes was obtained using 0.5µg Adr + 10µg atenolol 
+ 100µg INH.  Where as the addition of 0.5µg Adr + 10µg atenolol + 
200µg INH result in % change of 17.34. 
 
 A -2.10% change was obtained using 0.5µg Adr + 10µg atenolol + 
400µg CQ.  A -5.26% change was obtained using 0.5µg Adr +10µg 
atenolol + 800µg CQ. 
 
 A1.1% change was obtained using 0.5µg Adr + 10µg atenolol + 
100ug QNE.  Where as the addition of 0.5µg Adr + 10µg atenolol + 
200µg QNE result in a percent change of 2.2 . 
 
 A 1.88% change was obtained using 0.5µg Adr + 10µg Tolz + 
100µg INH.  Where as the addition of 0.5µg Adr + 10µg Tolz + 200µg 
INH result in a -1.88 %  change. 
 
 A -2.8% change was obtained using 0.5µg Adr + 10µg Tolz + 
400µg CQ.  A -4.3 % change was obtained using 0.5µg Adr + 10µg Tolz 
+ 800µg CQ. 
 
 The addition of 0.5µg Adr + 10µg Tolz + 100µg QNE result in a 
percent change of -5.3.  A -10.5% change obtained using 0.5µg Adr + 
10µg Tolz + 200µg QNE. 
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DISCUSSION 
Sudan is considered to be one of tropical countries, where 
endemic diseases like malaria, tuberculosis and leishmaniasis are 
prevalent. Patients with chronic diseases such as hypertension, 
myocardial infarction and diabetes mellitus may encounter, drug 
interaction which may occur if the patient was being infected with one 
and/or two of the tropical diseases.  In case of hypertensive patient been 
treated with atenolol or proprandol, and already suffering from 
tuberculosis which one of its drug regimen is isoniazid (INH). On the 
other hand a hypertensive patient been infected with malaria and under 
the therapy with chloroquine. 
As mentioned above the need arises to study the possible drug 
interactions been encountered in patients with special emphasis to 
tropical area. 
One of the objectives of this research is to study in vitro and/or 
isolated tissue the anticipated drug interactions and how to overcome 
them.  Special consideration is paid towards the possibility of cost 
effectiveness in such combined therapy. 
INH when added to isolated rabbit aortic strip in the presence of 
adrenaline significant dose dependent contraction, that inhibited partially 
by atenolol (β1-antagonist) and disappeared completely by tolazoline                          
(α-antagonist) (Fig. 1.1). INH in a dose of 100 µg/ml – 200 µg/ml 
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furtherly contracted the adrenaline stimulated isolated aortic strip. The 
effects of both adrenaline and INH were inhibited by tolazoline in a dose 
of 10 µg/ml (Fig. 1.1). However, INH when added to the in situ frog heart 
showed no significant inhibition to the heart contractility.  
Chloroquine when added in a dose of (800µg/ml) with adrenaline 
to isolated rabbit aortic strip showed no significant contraction and the 
effect is disappeared in presence of atenolol and tolazoline (Fig. 1-2).  
However, the addition of quinine in different doses with 
adrenaline to isolated aortic strip produced no significant effect (Fig. 1.3), 
quinine when added to in situ frog heart showed no significant effects on 
heart peaks even in higher doses (Fig. 1.6). These results indicates that 
quinine has no significant effect neither on aortic strip, nor on frog heart.  
This indicates that INH may act mainly as α- stimulator (an a dose of           
100 – 200 µg/ml).  However, when INH added to the in situ frog heart it 
showed slight inhibition to the heart contractility, and this may be by 
another mechanism since it showed no effect on the isolated rabbit strip 
(Fig. 1-3.3).   
Chloroquine when added in a dose of (800ug/ml) with adrenaline 
to isolated rabbit aortic strip showed significant contraction which 
disappeared in the presence of atenolol and tolazoline (Fig. 1.2). 
 However, the addition of Quinine in different doses with 
adrenaline to isolated aortic strip produced showed no significant effect 
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(Fig. 1.3) Quinine also when added to the in situ frog heart showed no 
significant effect on the heart peaks even in higher doses (Fig. 1.6).  
These results indicates that Quinine has no significant effect neither on 
the aortic strip nor on the heart, so it may be safe when used in 
hypertensive patients.  
In the attempt to study whether INH has any stimulatory effect on 
the rat was deferens; INH in a dose of up to 500 µg/ml slightly 
potentiated the effect of adrenaline in a dose of 2 mg/ml (Fig. 1.3.2). Also 
in rat was deferens, INH in a dose of 2 mg/ml was without effect but 
when administered in a dose of 500 mg/ml slightly potentiated the effect 
of adrenaline in a dose of 1mg/ml (Fig. 1.3.2).  
The effect of INH in a high dose was investigated on the rabbit 
aortic strip, as INH in different doses; 100 – 200 mg/ml showed no effect 
on the aortic strip (Fig. 1.3.3).  
We concluded that however, despite the fact that β-blockers are 
known to interact with a number of other drugs, there was been little 
evidence of suggest that most of these interactions are clinically 
important (Denis, 1984).  
Pharmacodynamic interactions are the most important among            
β-blockers (Denis, 1984).   
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Non-selective β-blockers antagonize B2-receptor mediated 
vasodilation, this allowing unopposed α-receptor mediated 
vasoconstriction particularly in the presence of catecholamines (Denis, 
1984) and this mechanism might be shown on (Fig. 1.2).  
When atenolol was added in a dose of 10 mg/ml concurrently 
with adrenaline in a dose of 0.5µ/ml showed slight contraction on the 
rabbit aortic strip.     
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CONCLUSION AND RECOMMENDATIONS  
 
Regarding β-blockers interactions with other drugs, only the 
pharmacodynamic interactions are likely to have serious consequences 
(Denis, 1984).  
Chloroquine in a dose of 800 mg/ml is most likely to potentiate 
the effect of adrenaline in a dose of 0.5 mg/ml  
Isoniazid (INH) clearance is affected by the concurrent use of            
β-blockers (Denis, 1984) and this established pharmacokinetics 
interaction.  
INH might have stimulatory effect (dose of 500 mg/ml) in the 
presence of adrenaline on rat was deferens.  
β2-blockers allowed the unopposed α-receptor mediated 
vasoconstriction particularly in presence of catecholamines. 
Care also should be taken in case of patients suffering from 
myocardial infarction receiving chloroquine concurrently. As tachycardia 
due to the effect of chloroquine may exacerbate the disease condition.  
Isoniazid (antitubercular drug) may exhibit α-receptor 
stimulatory effect, so possible interaction may occur in patient with 
hypertension.  
It is recommended that drugs like isoniazid and chloroquine 
should be avoided and/or used with care in patients suffering from such 
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chronic disease, e.g. hypertension, and ischaemic heart diseases as 
myocardial infarction.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 77
REFERENCES 
Bertram G. Katzung. Basic & clinical pharmacology. Eight edition 2001. 
Middle East edition Copyright 2001 by the MC Gram-Hill 
companies, Inc. 
Brett R, David CL, John T, Van De Voort, John G. Benitez, Halamka J, 
Raymond JR. Toxicity of  B-blockers. www.Emedicine. Com.  
Bruce LJ. Chemotherapy of malaria. 1986; 56, WHO. 119 – 166.  
Denis G. McDevitt. Interaction that matter: B-adrenoceptor antagonists. 
Medicine digest J 1988; P. 15-16.  
Furchoghtt RF, Bhadrakom. Reaction of strip of aorta to epinephernine, 
Sodium nitate and other drugs. J Exper Pharmacol Therape 1953; 
108: 129 – 143.  
Ian K. Textbook of in vitro practical pharmacology, Oxford:  Blackwell 
Scientific Publication; 1988. P. 113 – 114,    
Kirch W, Kohler H, Mutschler E. Pharmacokinetics of atenolol in relation 
to renal function. Eur J Pharmacol 1981; 19: 65 – 72.  
Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E. 
Interaction of atenolol with furosemide and calcium and aluminium 
salts. Clin Pharmacol Thera 1981; 30: 429 – 435.  
Lundborg P, Regardh CG. Food, antacids and bioavailability of beta-
blokers. International conference on Drug abdorption, Edinburgh, 
1979.  
 78
Rang HP, Dale MM. Antibacterial drugs, pharmacology, 4th ed. Churchill 
Livingstone 1999; 703- 704.  
Rang HP, Dale MM, Ritter JM. Antimalarial drugs, pharmacology,                
4th ed. Churchill Livingstone 1999; 729 – 730.  
Reith DM, Dawson AH, Sayer NA. Relative toxicity of beta blockers in 
overdose. J Toxicol Clin 1996; 34(3): 273 – 8.  
Roger W, Clive E. Hypertension and diabetes mellitus. In: Roger W, 
(editor) Clinical pharmacy and therapeutics. London: Churchill 
Livingstone; 1999. P. 247 -255; 633 – 647.   
Staff of Medicine Information Centre. Malaria update 1997. The Journal 
of Modern Pharmacy, Vol. 5 No. 3: 1998 Cape Town.  
Staff of the Department of Pharmacology, University of Edinburgh, 2nd 
ed. Churchill Livingstone, P. 2.   
 Mary J. Mycel, Richard HP. Anti-mycobacterial drugs, Lippincott’s 
illustrated review, 2nd ed. New York:  Lippincot Williams & 
Wilkins; 2000. P. 331 - 32.  
Monica SK, Wihem K, Thilo A, Hans K, Ernst M. Atenolol interation 
with aspirin, allopurinol and ampicillin. Clinical Pharmacology and 
therapeutic 33(3): 283 - 288.  
Talabiska DG, Komar MJ, Wytoch NH, Rubin RA. Pre-existing liver 
disease. Am J Gastrointerol 1996; 91(2): 386 – 379.  
  
